Prospects for advancing tuberculosis control efforts through novel therapies

PLoS Medicine

Volumn 3, Issue 8, 2006, Pages 1302-1309

  Salomon, Joshua A ^a,b   Lloyd Smith, James O ^c,d   Getz, Wayne M ^c   Resch, Stephen ^b   Sánchez, María S ^c   Porco, Travis C ^e   Borgdorff, Martien W ^f,g  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b Harvard Initiative for Global Health   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d PENNSYLVANIA STATE UNIVERSITY   (United States)

^e Tuberculosis Control Branch   (United States)

^f KNCV TUBERCULOSIS FOUNDATION   (Netherlands)

^g UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

TUBERCULOSTATIC AGENT;

ARTICLE; CALIBRATION; CHEMOTHERAPY; CONTROLLED STUDY; HUMAN; LUNG TUBERCULOSIS; MATHEMATICAL MODEL; MORBIDITY; MORTALITY; SOUTHEAST ASIA; TREATMENT DURATION; TUBERCULOSIS CONTROL; WORLD HEALTH ORGANIZATION; DIRECTLY OBSERVED THERAPY; DRUG ADMINISTRATION; DRUG DESIGN; INCIDENCE; INFECTION CONTROL; PATIENT COMPLIANCE; RECURRENT DISEASE; THEORETICAL MODEL; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; ASIA, SOUTHEASTERN; COMMUNICABLE DISEASE CONTROL; DIRECTLY OBSERVED THERAPY; DRUG ADMINISTRATION SCHEDULE; DRUG DESIGN; HUMANS; INCIDENCE; MODELS, THEORETICAL; PATIENT COMPLIANCE; RECURRENCE; TUBERCULOSIS; WORLD HEALTH ORGANIZATION;

EID: 33748360765     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.0030273     Document Type: Article

References (22)

1. World Health Organization (2005) WHO report 2005: Global tuberculosis control: Surveillance, planning and financing. Report number WHO/HTM/TB/2005.349.
2. Styblo K, Meijer J, Sutherland I (1969) Tuberculosis Surveillance Research Unit Report No. 1: The transmission of tubercle bacilli; its trend in a human population. Bull Int Union Tuberc 42: 1-104.
3. Wilson LG (1990) The historical decline of tuberculosis in Europe and America: Its causes and significance. J Hist Med Allied Sci 45: 366-396.
4. Vynnycky E, Fine PE (1997) The annual risk of infection with Mycobacterium tuberculosis in England and Wales since 1901. Int J Tuberc Lung Dis 1: 389-396.
5. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, et al. (2003) The growing burden of tuberculosis: Global trends and interactions with the HIV epidemic. Arch Intern Med 163: 1009-1021.
6. WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance (2004) Anti-tuberculosis drug resistance in the world: Third global report. Report number WHO/HTM/TB/2004.343.
7. Sachs JD (2004) Health in the developing world: Achieving the Millennium Development Goals. Bull World Health Organ 82: 947-949.
8. United Nations Millennium Project (2005) Millennium Development Goals. Available at: http://www.un.org/millenniumgoals. Accessed 15 June 2006.
9. Stop TB Partnership (2001) Global plan to stop TB, 2000-2005. Report number WHO/CDS/STB/2001.16.
10. Dye C, Watt CJ, Bleed DM, Williams BG (2003) What is the limit to case detection under the DOTS strategy for tuberculosis control? Tuberculosis (Edinb) 83: 35-43.
11. World Health Organization (2003) Treatment of tuberculosis: Guidelines for national programmes. 3rd edition. Report number WHO/CDS/TB/2003.313.
12. O'Brien RJ, Spigelman M (2005) New drugs for tuberculosis: Current status and future prospects. Clin Chest Med 26: 327-340.
13. Stover CK, Warrener P, VanDevanter DR, Sherman DR, Arain TM, et al. (2000) A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 405: 962-966.
14. Lenaerts AJ, Gruppo V, Marietta KS, Johnson CM, Driscoll DK, et al. (2005) Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob Agents Chemother 49: 2294-2301.
15. Andries K, Verhasselt P, Guillemont J, Gohlmann HW, Neefs JM, et al. (2005) A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307: 223-227.
16. Nuermberger EL, Yoshimatsu T, Tyagi S, Williams K, Rosenthal I, et al. (2004) Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am J Respir Crit Care Med 170: 1131-1134.
17. Alvirez-Freites EJ, Carter JL, Cynamon MH (2002) In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 46: 1022-1025.
18. Dye C, Garnett GP, Sleeman K, Williams BG (1998) Prospects for worldwide tuberculosis control under the WHO DOTS strategy. Directly observed short-course therapy. Lancet 352: 1886-1891.
19. Blower SM, Small PM, Hopewell PC (1996) Control strategies for tuberculosis epidemics: New models for old problems. Science 273: 497-500.
20. Murray CJ, Salomon JA (1998) Modeling the impact of global tuberculosis control strategies. Proc Natl Acad Sci U S A 95: 13881-13886.
21. Cohen T, Murray M (2004) Modeling epidemics of multidrug-resistant M. tuberculosis of heterogeneous fitness. Nat Med 10: 1117-1121.
22. Mahadev B, Kumar P (2003) History of tuberculosis control in India. J Indian Med Assoc 101: 142-143.